It can effectively increase myocardial nutritional blood flow and improve myocardial microcirculation; it can reduce myocardial oxygen consumption; it can significantly reduce serum cholesterol; it can reduce or inhibit the formation of atherosclerotic plaques and liver lipid deposition.

It can effectively increase myocardial nutritional blood flow and improve myocardial microcirculation; it can reduce myocardial oxygen consumption; it can significantly reduce serum cholesterol; it can reduce or inhibit the formation of atherosclerotic plaques and liver lipid deposition.

Rizatriptan has a high affinity for cloned human 5-HT1B and 5-HT1D. It has a lower affinity for other 5-HT1 receptors and 5-HT7 receptors, and has no significant activity on 5-HT2, 5-HT3, adrenaline, DA, histamine, choline or BZ receptors. Rizatriptan stimulates the 5-HT1B/1D on the extracerebral and intracranial blood vessels and trigeminal nerve endings that dilate during a migraine attack, causing intracranial vasoconstriction and inhibiting the release and transmission of neuropeptides in the trigeminal nerve pain pathway, thereby exerting its therapeutic effect on migraine.

Cytidine diphosphocholine (CDPC) is a nucleoside derivative with the chemical name cytidine diphosphocholine. It participates in the biosynthesis of lecithin in the body and is a brain metabolism activator. It can enhance the function of the ascending reticular formation activation system, reduce cerebrovascular resistance, increase cerebral blood flow, improve cerebral blood circulation, promote brain substance metabolism, and restore function.